femoston 1mg+1mg/10mg potahovaná tableta
viatris healthcare limited, dublin array - 13226 hemihydrÁt estradiolu; 13226 hemihydrÁt estradiolu; 6073 dydrogesteron - potahovaná tableta - 1mg+1mg/10mg - dydrogesteron a estrogen
femoston 2mg+2mg/10mg potahovaná tableta
viatris healthcare limited, dublin array - 13226 hemihydrÁt estradiolu; 13226 hemihydrÁt estradiolu; 6073 dydrogesteron - potahovaná tableta - 2mg+2mg/10mg - dydrogesteron a estrogen
femoston conti 1mg/5mg potahovaná tableta
viatris healthcare limited, dublin array - 13226 hemihydrÁt estradiolu; 6073 dydrogesteron - potahovaná tableta - 1mg/5mg - dydrogesteron a estrogen
femoston mini 0,5mg/2,5mg potahovaná tableta
viatris healthcare limited, dublin array - 13226 hemihydrÁt estradiolu; 6073 dydrogesteron - potahovaná tableta - 0,5mg/2,5mg - dydrogesteron a estrogen
femoston 1/10 estradiol 1mg and estradiol 1mg with dydrogesterone 10mg tablet blister pack
viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; hypromellose; maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.,hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).
femoston 2/10 estradiol 2mg and estradiol 2mg with dydrogesterone 10mg tablet blister pack (cp)
viatris pty ltd - dydrogesterone, quantity: 10 mg; estradiol, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; colloidal anhydrous silica; lactose monohydrate; maize starch; titanium dioxide; iron oxide yellow; purified talc; macrogol 400 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).
femoston-conti tablet blister pack
viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hypromellose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 400 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.
femoston 2/10
abbott biologicals b.v. - olanda - combinatii (estradiolum + didrogesteronum) - compr. film. - progestative si estrogeni in combinatii progestative si estrogeni preparate secventiale
femoston 2/10
abbott biologicals b.v. - olanda - combinatii (estradiolum+didrogesteronum) - compr. film. - progestative si estrogeni in combinatii progestative si estrogeni preparate secventiale
femoston comprimate filmate 2 mg; 2 mg + 10 mg
abbott healthcare products b.v. - estradiolum + dydrogesteronum - comprimate filmate - 2 mg; 2 mg + 10 mg